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ABSTRACT
Triclosan is widely employed in many consumer and healthcare products. The increasing employment
of triclosan in a range of consumer products where there is no proven beneﬁt for hygiene has been
severely criticised. Laboratory studies demonstrate theoretical risks that the wide-scale use of triclosan
might compromise its efﬁcacy as well as the activity of third-party antibiotics. The precautionary
principle would dictate against the use of triclosan, at least in those products where there was no
demonstrable health beneﬁt. The theoretical risks, however, are not supported by either ﬁeld or clinical
studies, or by laboratory studies using bacterial microcosms. Numerous clinical studies, as well as
historical data, demonstrate the clinical beneﬁts of hygiene adjuncts such as triclosan and triclosan ⁄ co-
polymer in oral care products where these compensate for deﬁciencies in mechanical hygiene (brushing
and ﬂossing). The balance of risk and beneﬁt is ﬁrmly in favour of the continued use of dentifrices
(toothpastes) and mouthwashes containing active agents such as triclosan.
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INTRODUCTION
The primary factor in good oral health is the
routine control of dental plaque, a natural bioﬁlm,
formed on tooth surfaces and compacted at
gingival margins. Such plaque is associated with
caries, and gum inﬂammation (gingivitis) or
degradation (periodontitis) of the gums and
proximal bone. Root canal infection and chronic
periodontitis lead to continual challenge of the
systemic circulation by a plethora of oral micro-
bes, either singly or as ‘septic infarcts’ originating
from the gingival pocket or tooth-pulp [1]. The
articles in this issue present overviews of the
potential of such chronic inﬂammation, and overt
infection, to predispose individuals to cardiovas-
cular disease either directly or indirectly [1]. In
this context, oral health is not only important
from an aesthetic standpoint, but is also central to
the general wellbeing of individuals and poten-
tially to both the quality and length of life. The
single most important route to oral health, in an
otherwise healthy individual, is regular and
appropriate hygiene. However, over 90% of
adults in Western Europe must resort to repara-
tive dental work and over 50% have some form of
periodontal disease [2,3], while the majority claim
to brush their teeth at least twice-daily [4].
Although many factors, such as genetics, smoking
and diabetes, inﬂuence the susceptibility of an
individual to periodontitis, the process of tissue
destruction is initiated by plaque bacteria and
can be controlled by regular brushing. Active
ingredients in oral care products, such as denti-
frices and mouthwashes, have the potential to
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compensate for shortfalls by having signiﬁcant
effects on the vitality of dental bioﬁlm, but they
do not substitute for appropriate mechanical
cleansing. The efﬁcacy of such products, particu-
larly those employing triclosan ⁄ copolymer, is
supported by numerous clinical studies [4], where
the evidence in favour of triclosan use in oral
hygiene is overwhelming. In spite of this proven
efﬁcacy and a greater understanding of the
possible links between oral health and systemic
infection, routine use of such products has been
criticised on the basis of theoretical risks of
antibiotic resistance development.
Over three decades, with the exception of
sporadic reports of triclosan insensitivity, there
has been no general reduction in the effectiveness
of this agent against its target bacteria. Recent
developments in home and household products
have, however, dramatically increased the envi-
ronmental exposure to triclosan. Such novel,
market-driven applications have been subject to
severe criticism in view of the absence of proven
beneﬁt for hygiene to offset the theoretical
potential for resistance development. Laboratory
studies demonstrating such potential have con-
centrated on enteric bacteria or pseudomonads,
even though triclosan is not noted for its activity
against either. Long-term, sub-lethal exposure of
Escherichia coli to triclosan can lead to the selection
of mutant clones with signiﬁcantly reduced sus-
ceptibility, either mutated in an enoyl-reductase
enzyme (FabI) or overexpressing multidrug efﬂux
pumps. Initial concerns that mutations in FabI
might be capable of horizontal transfer between
environmental bacteria and nosocomial patho-
gens, or that parallel processes might occur
directly in Gram-positive pathogens, have sub-
sided. Similarly, concern about possible selection
of resistance towards third-party agents (antibi-
otics) that might share the FabI gene target have
proven unfounded. Although efﬂux mutants have
been demonstrated in the laboratory, they have
not been observed in retrospective analyses of
isolates from the hospital or domestic environ-
ment, where agents such as triclosan have been
widely employed, suggesting that efﬂux-on and
FabI mutants are unable to compete in natural
microbial communities.
This review will consider the evidence associ-
ated with triclosan-associated changes in suscep-
tibility of organisms in both laboratory and ﬁeld
studies.
BACKGROUND
Triclosan is the most commonly used and most
potent example of the chlorinated diphenyl ether
class of antibacterial compounds [5]. Since its
introduction in the 1960s, it has been widely used
as an antiseptic in clinics and hospitals [6,7],
within medicated soaps and hand-washes and as
therapeutic baths for methicillin-resistant Staphy-
lococcus aureus-infected patients [8,9]. The efﬁcacy
of triclosan in the control of methicillin-resistant
S. aureus skin infections is proven [10,11] and is its
main beneﬁt in antiseptic hand-washes for labo-
ratory and hospital surgical ⁄medical units [7].
Triclosan has also been employed widely in a
variety of personal products, including sham-
poos, toothpastes, and deodorants [12–14].
Over the past 10 years, the broad-spectrum
antimicrobial activity of triclosan has led to its
incorporation in an extended range of product
formulations intended for home use. For example,
a recent survey of liquid soaps in the USA
revealed that 45% contained antibacterial agents,
most of which included triclosan [15]. A recent,
market-driven development has been the intro-
duction of hardware products composed of plas-
tics that have triclosan incorporated within them.
Such products, marketed in the name of hygiene,
claim to confer a degree of colonisation resistance
to a wide variety of objects, including chopping
boards, children’s toys, carpets, and food storage
containers. The hygienic gains associated with
this new and increasingly widespread use in the
home are largely undemonstrated.
Triclosan is a broad-spectrum antimicrobial
agent that is especially active against Gram-
positive species such as S. aureus, but it is
ineffective against the Pseudomonadaceae [5].
The bias away from Gram-negative species is
responsible for its widespread use in topical
healthcare applications and in oral hygiene.
Triclosan differs from more conventional agents
of this class, e.g., strong oxidisers, bisbiguanides
and aldehydes, in that the majority of environ-
mental species, including many yeasts, are not
susceptible.
When ﬁrst introduced, triclosan was thought to
act in a fashion similar to other halogenated
phenols such as tricarbamilide, pentachlorophe-
nol, and trichlorocarbanilide [16], by interacting
with cell membranes to cause non-speciﬁc cyto-
plasmic losses [16]. Lack of susceptibility in the
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Pseudomonadaceae was attributed to exclusion,
by the outer-membrane, from the more vulnera-
ble cytoplasmic membrane [17]. Mechanistic stud-
ies failed to distinguish between an entire class
of membranotropic antimicrobial agents that
included bisbiguanides, quaternary ammonium
compounds [18], surfactants, phenylethers, and
phenoxyethers. Many of these molecules were
noted as uncouplers of oxidative phosphorylation
from respiration; this has recently been conﬁrmed
for triclosan [19]. Uncoupling depletes the ATP
pool [18] and disrupts ATP biosynthesis, active
transport and osmoregulation, leading to growth
inhibition through a multiplicity of targets [17,18].
Such a multiplicity of targets underpins our
conﬁdence that resistance will not develop. Many
environmental organisms, including many of the
Pseudomonadaceae, Actinomycetes and spore-
forming bacilli, do not succumb to these and can
actively degrade triclosan.
The discovery that chronic, sub-lethal exposure
of E. coli to triclosan can lead to the selection of
mutant clones that possess a signiﬁcantly reduced
MIC [20–24] has led to an upsurge of interest in its
pharmacology. Triclosan has proved to be a
potent inhibitor of the enoyl acyl carrier protein
(ACP) reductase (FabI) of E. coli [20,21,24], an
essential enzyme in fatty acid biosynthesis for
many bacterial species, including Gram-positives
[20,22,23]. The enzyme is conserved among bac-
terial species, with homologous target enzymes
(InhA) being functionally important in various
mycobacteria, bacilli and staphylococci [25]. Nat-
urally occurring triclosan-resistant ACPs (InhK)
have been documented. Pseudomonas aeruginosa
possesses both triclosan-sensitive and triclosan-
resistant FabI homologues. In species such as
E. coli, triclosan can select for FabI mutants that,
for this relatively insensitive organism, are toler-
ant of the agent at high concentration [21,24]. If
this was replicated in Gram-positive bacteria, and
if ACP was the sole target, then such mutations
would signiﬁcantly decrease triclosan’s efﬁcacy.
Importantly, if ACPs were a target for other
therapeutic agents and the ACP of Mycobacterium
tuberculosis is the target for isoniazid, then their
activity might also be compromised [26]. McMur-
ry et al. demonstrated that partial isoniazid resis-
tance in Mycobacterium smegmatis could be
conferred by mutations in InhA, the gene homol-
ogous to Fabl [25], but isoniazid-selectedM. tuber-
culosis mutants remain susceptible to triclosan,
suggesting separate interactive sites [27,28]. Selec-
tion of mutant ACPs by triclosan would be
problematic if antibiotics used for treating staph-
ylococcal and enterococcal infections shared this
target. This is, however, not the case; cross-
resistance has not been encountered for staphy-
lococci [29]. Rather, the major implication of
ongoing triclosan use is the possible selection of
triclosan-tolerant strains.
If the ACP enzymes were highly conserved and
equally important in all clinically relevant organ-
isms, there would be a remote possibility of
horizontal transmission of tolerance from envi-
ronmental to clinically important organisms.
Thus, it can be argued that triclosan should be
conﬁned to those applications where there are
proven gains in hygiene. Recent publications
suggest, however, that, not only is the ACP
function conferred by a variety of isoenzymes,
but even those with a high degree of homology to
the FabI of E. coli possess signiﬁcant functional
differences.
Heath et al. conducted molecular studies con-
cerning the interaction of triclosan with Gram-
positive bacteria [22,23]. They identiﬁed the FabI
component of S. aureus (saFabI) and found that
the homologues from E. coli had similar speciﬁc
activities, and also that S. aureus FabI expression
complemented that of E. coli FabI (Ts). While
staphylococcal FabI was interchangeable with the
E. coli FabI enzyme, the latter was speciﬁc for
NADH, whereas the staphylococcal enzyme
exhibited speciﬁc and positive cooperative bind-
ing of NADPH. Triclosan inhibited both enzymes,
but triclosan-resistant forms were hexachloro-
phene-sensitive and hexachlorophene-resistant,
respectively. By contrast, Heath et al. identiﬁed
considerable homology between the E. coli ACP
and that of Bacillus subtilis, but noted an equal
preference for NADH or NADPH as a cofactor.
B. subtilis was noted to possess a second ACP
homologue, but it was substantially less suscep-
tible to triclosan and could functionally replace
the FabI homologue.
Research concentrating on the interaction of
triclosan with ACP enzymes loses sight of the
multi-targeted mechanisms of this and structur-
ally related biocides [16,30,31]. While triclosan is
different from other chlorinated phenolics, be-
cause its inhibitory action centres on one enzyme,
bactericidal activity involves a plethora of non-
speciﬁc perturbations. Villalain et al. [30] showed
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that triclosan disrupts the membrane integrity of
typical oral bacteria, which are actively lysed at
‘use’ concentrations, reinforcing the view that
triclosan is primarily a membranotrophic agent.
Differences in ACP enzymes between Gram-
positive and Gram-negative bacteria are insufﬁ-
cient to explain their marked differences in
susceptibility.
Early work attributed the ‘intrinsic’ resistance
of Gram-negative bacteria to the presence of an
impenetrable outer-membrane [32]. There is now
very strong evidence that this barrier is aug-
mented by the expression of efﬂux pumps, capa-
ble of actively removing many inimical agents
from the cell [33]. Efﬂux pumps such as acrAB can
be up-regulated through the multiple antibiotic
resistance (mar) operon in response to sub-lethal
stress due to certain inducer substances (tetracy-
cline and salicylates [34], pine-oil [35], and qua-
ternary ammonium compounds [36]). Induction
of efﬂux is sufﬁcient to confer clinical resistance to
many therapeutic agents, but is generally insufﬁ-
cient to inﬂuence the outcome of strong biocidal
treatments [37]. Efﬂux is a highly evolved defence
mechanism against a wide range of environmen-
tal toxins. Mutants that constitutively express
efﬂux pumps suffer a heavy ﬁtness-cost and will
generally not be competitive in nature without a
favourable selection pressure. In Gram-negative
bacteria, sub-lethal exposure to any efﬂux inducer
changes susceptibility to triclosan, which is a
substrate. Triclosan cannot induce efﬂux [21];
therefore, sub-bactericidal exposure of Gram-neg-
ative bacteria may select for spontaneous hyper-
expressing efﬂux mutants. Triclosan may thus
select for highly resistant clones of P. aeruginosa
[38], for which the MICs of several other drugs,





Much of the published work concerning triclosan
resistance has utilised pure cultures, which are
acknowledged to be unrepresentative of the ‘real
world’. Repeated passage of ex-vivo isolates
causes them to lose non-essential traits. Thus,
triclosan-insensitive E. coli strains were selected
during routine and repeated passage against
triclosan in monoculture [21,25], identifying
ACP as a major target of this biocide; such stable
reductions in triclosan susceptibility have been
repeated by other groups using E. coli [39–41]. In
contrast, replication of these selection ⁄ training
protocols, using over 40 fresh isolates from the
mouth, skin and domestic drain, together with
representative laboratory strains of typical oral
ﬂora (Fusobacterium nucleatum, Lactobacillus
rhamnosus, Neisseria subﬂava, Porphyromonas gingi-
valis, Actinomyces naeslundii, Prevotella nigrescens,
Streptococcus oralis, Streptococcus sanguis, Strepto-
coccus mutans and Veillonella dispar), showed that
only the enteric species E. coli and Klebsiella
oxytoca undergo selectable decreases in triclosan
susceptibility [39,42]. Their susceptibilities to
third-party agents were not signiﬁcantly
decreased. None of the remaining test isolates,
including other enteric species such as salmonel-
lae, were affected in terms of their susceptibility
to triclosan or to any representatives of the test
panel [39,42], which showed that the ability to
select for triclosan resistance is not universal and
might even be restricted to E. coli. The multiplic-
ity of ACP in many bacterial genera and differ-
ences in susceptibility to triclosan mean that, in
other species, there might be more susceptible
targets than FabI which may dictate triclosan
activity. Alternatively, susceptibility could be
dependent on non-speciﬁc action at the level of
the cytoplasmic membrane [19,43]. In both in-
stances, the presence of multidrug efﬂux pumps
will greatly decrease bioavailability at the phar-
macological target. In this respect, high-level
triclosan-resistant mutants of E. coli are not only
affected in their ACP enzymes, but also hyper-
express multidrug efﬂux pumps such as acrAB.
P. aeruginosa, an organism inherently insensitive
to triclosan, requires deletion of the major efﬂux
pumps (mexA, mexB) for triclosan sensitisation.
Interestingly, when P. aeruginosa is sensitised to
triclosan by removal of these pumps, triclosan
training selects for strains with the otherwise
unexpressed pumps (mexC, mexD) [38]. Triclosan
is unusual in that it is a substrate for many
different efﬂux pumps, but does not regulate
them. Pump-mediated resistance to triclosan
requires cells to be up-regulated, through an
unrelated third-party inducer, or constitutive
expression. Sub-lethal triclosan exposure of E. coli
may select for pre-existing constitutive mutants
that hyper-express efﬂux pumps. It has been
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argued that multidrug efﬂux pumps, while con-
ferring resistance to clinically useful antibiotics,
have evolved to contend with naturally occurring
inimical agents [44]. Rickard et al. [44] investi-
gated the potential of non-antibacterial consumer
products to induce the multiple antibiotic resis-
tance (mar) operon of E. coli. Of 35 products tested
(nine herbs and spices, 19 foods and seven
household products), 24 (69%) products were
bacteristatic and 22 (63%) induced mar expres-
sion. Six products were shown to be powerful
mar inducers but none were claimed to affect
hygiene and none contained triclosan. The
authors concluded that mar can be induced by
exposure to many natural substances, common to
the domiciliary setting. Concern that antibacterial
agents deliberately added to consumer products
might select for mar-mediated resistance was
short-sighted and failed to recognise the ubiquity
of inducers in the environment.
Microcosm studies
Pure cultures maintain organisms within a nutri-
tious environment devoid of competition. Debil-
itated strains can be perpetuated as pure cultures
in the laboratory but are unable to compete in the
environment. In the ‘real world’, microrganisms
grow as polymicrobial communities, often in
close proximity to one another and attached to
surfaces (bioﬁlms). Bioﬁlms are ubiquitous in
nature, where phenotypic and genetic diversity
confer metabolic capacities that are greater than
the sum of the individual community members.
Survival within such a community is dependent
upon ﬁtness and cross-species interaction. Few
environments are colonised by pure cultures.
Rather, multiple-species bioﬁlms dominate in
locations such as domestic sink drains, the human
mouth and gut, sewers and sewage treatment
plants. All of these environments will be exposed
to varying levels of triclosan, because of its use in
domestic cleaning formulations and dentifrices.
Accordingly, we have evaluated the effects of
chronic, low-level triclosan exposure on such
communities.
Domestic drain studies
Stable sink-drain bioﬁlms were established, using
constant-depth ﬁlm fermenters and ex-situ drain
bioﬁlm material from a household that had not
used triclosan-containing products, other than
dentifrices [45]. Microcosms, intermittently fed
with artiﬁcial dishwater, were maintained at
room temperature and constantly moistened with
untreated tap water. Cultured microcosms closely
modelled the ex-situ material [45] and were used
to investigate the long-term effects (6 months) of
exposure to a triclosan-containing domestic deter-
gent. Culturable bacteria were archived and
antimicrobial susceptibilities were determined.
There was a general lack of sensitivity in the
evolved bioﬁlm community to triclosan and
cationic soaps. Triclosan-tolerant strains of Aero-
monas, Pseudomonas, Stenotrophomonas and Alcalig-
enes spp. were detected before and after triclosan
exposure. Triclosan products did not select for
resistance; rather, they affected community
dynamics, causing clonal expansion of pre-exist-
ing, less susceptible clones, among which pseu-
domonads dominated. Achromobacter xylosoxidans,
an organism later shown to solubilise and
degrade triclosan, expanded clonally. There was
no change in the triclosan susceptibility of any
isolate, and susceptibility to a panel of third-party
antibiotics was unchanged.
Dental plaque studies
The potential effects of a triclosan ⁄ copolymer
dentifrice on oral microcosms was also studied
using constant-depth ﬁlm fermenters [46]
exposed to triclosan at levels equivalent to a
normal hygiene regimen [46]. Bacteria exhaus-
tively isolated on various selective media and
microcosm plaques were proﬁled using denatur-
ing gradient gel electrophoresis (DGGE); the
isolates were archived and susceptibility to a
range of antibiotics was determined. Triclo-
san ⁄ copolymer caused signiﬁcant reductions in
Gram-negative anaerobes and the total anaerobe
count. Transient reductions were noted, accord-
ing to both culture and non-culture methods, in
the numbers and diversity of streptococci and
actinomycetes. Parallel studies using type cul-
tures of oral bacteria indicated that N. subﬂava,
P. nigrescens and P. gingivalis were highly suscep-
tible to triclosan and that the lactobacilli and
streptococci were relatively non-susceptible [46].
Both datasets were compatible with the hypo-
thesis that repeated exposure of oral microcosms
to triclosan ⁄ copolymer inhibits the most suscep-
tible ﬂora and causes clonal expansion of less sus-
ceptible species. This picture is also compatible
with in-vivo studies. In no instance was there any
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change in the susceptibility proﬁle of the isolated
species that could be attributed to triclosan.
Environmental surveillance studies
The availability of oral hygiene formulations
containing adjuncts that inhibit the formation
and development of dental plaque and that are
intended to improve other indices of oral health
has resulted in guidelines from the American
Dental Association and the US Food and Drug
Administration to monitor effects on oral micro-
ﬂora. Eight long-term studies (6 months or longer
with more than 650 subjects) have examined the
microbiological effects of the unsupervised use of
triclosan formulations as compared with those of
appropriate control dentifrices [47–50]. Qualita-
tive and quantitative evaluations of the oral
microﬂora were made, with particular reference
not only to the emergence of opportunistic patho-
gens, but also to the possible development of
microbial resistance, either during the 6-month
test period or during a 6-month post-exposure
surveillance period. Results from some of these
studies were reviewed for both safety and efﬁcacy
of triclosan ⁄ copolymer by the US Food and Drug
Administration and the American Dental
Association [47,48]. Signiﬁcantly, in no instance
were there reported changes in antimicrobial
susceptibility of the oral microﬂora, or dysbiosis
of a healthy ﬂora during or after exposure. The
clinical studies report that a beneﬁcial oral
ﬂora was maintained within the dental plaque,
with no emergence of periodontal or opportu-
nistic pathogens, including yeasts, among the
subjects.
Other long-term studies (3–5 years with more
than 500 subjects) examined the effects of brush-
ing with triclosan ⁄ copolymer dentifrice upon the
severity of periodontitis or the nature of the
subgingival microﬂora [51–54]. Once again, no
alterations in antimicrobial susceptibility were
reported in any of these studies, and nor were
adverse changes in composition of the oral
microﬂora in the subgingival regions noted.
Reductions in the progression of periodontal
disease were reported among the triclosan ⁄
copolymer group [54]. Overall decreases in the
subgingival ﬂora, with fewer subjects harbouring
periodontal pathogens, i.e., P. gingivalis, Prevotella
intermedia and Actinobacillus actinomycetemcomi-
tans, were reported [53].
Beyond the immediate effects on oral ﬂora,
interest has been focused on environments subject
to the greatest exposure to triclosan and other
antibacterial agents. Cole et al. [55] studied 60
homes in the USA and UK, selected on the
basis of antibacterial product use. Analysis of
the bacterial species present (1238 isolates)
demonstrated a greater proportion of potential
pathogens in non-user households. Neither meth-
icillin-resistant S. aureus nor strains resistant to
oxacillin or vancomycin were recovered, and nor
was there evidence of ampicillin- or vancomycin-
resistant enterococci. All E. coli and Klebsiella spp.
were susceptible to third-generation cephalospo-
rins. Antibiotic resistance to a single ‘preferred’
drug agent was not signiﬁcantly different be-
tween user and non-user households. Impor-
tantly, the incidence of resistance to antibacterial
agents was highest in non-user households. Lear
et al. [56] investigated industrial environments
where heavy biocide use is routine. While triclo-
san-tolerant isolates were retrieved, the authors
concluded that these were naturally tolerant Pseu-
domonas spp., and the data did not predict resis-
tance to normally lethal levels. No evidence linked
biocide residues to tolerance in the environments
investigated. A similar study evaluating clinical
isolates ofP. aeruginosa andS. aureus over a 10-year
period [57] revealed evidence of changes in sus-
ceptibility to biocides between 1989 and 2000 for
S. aureus, but failed to support the hypotheses that
increased biocide resistance had led to antibiotic
resistance. Negative correlations between antibi-
otic and biocide susceptibility were seen as ‘a
useful reason for the continued use of biocides in
the hospital environment’.
Aiello et al. [58] conducted a large (224 house-
holds), 12-month study into the potential effects
of antibacterial products in the domestic environ-
ment. This involved detailed microbial isolation
and analysis, and logistic regression analysis of
susceptibility data showed that the use of anti-
bacterial products did not generate a signiﬁcant
increase in antimicrobial drug resistance after
1 year and had not inﬂuenced overall suscepti-
bility to triclosan.
CONCLUSION
There is currently insufﬁcient evidence to afﬁrm
that the uncontrolled use of triclosan in domestic
products is totally free of risk. Every intervention
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must be evaluated according to the balance
between its risk to the consumer and environment
and its potential and real beneﬁts. The clinical
effectiveness of oral hygiene formulations con-
taining triclosan, including their role in the
prophylaxis and treatment of common oral mal-
adies, is unquestionable, and the risk of resistance
development following from triclosan use is
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